Meropur

Menotrophin, the active ingredient in Meropur, is a gonadotropin (FSH and LH preparation) presented as a sterile solution for intramuscular, subcutaneous use. It treats infertility in women by stimulating ovarian follicular development and ovulation. GNH USA supplies Meropur as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meropur is a gonadotropin preparation used in reproductive medicine to support follicular growth and ovulation. - Ovulation induction: promotes the development of a dominant follicle to trigger ovulation in anovulatory women. - Controlled ovarian hyperstimulation: enhances multiple follicle development for assisted reproductive technologies such as IVF. - Infertility treatment: improves the chances of conception in couples experiencing female factor infertility.

Adverse reactions may occur with Menotrophin therapy and are categorized by frequency.

Common Side Effects: - Injection site pain or erythema - Abdominal discomfort or bloating - Headache - Nausea or mild vomiting - Breast tenderness - Mild ovarian hyperstimulation

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS) - Multiple pregnancy - Allergic reactions including rash or anaphylaxis - Thromboembolic events - Pulmonary edema - Severe abdominal pain with ascites

Before initiating Menotrophin therapy, clinicians should consider several safety measures. - Baseline assessment: evaluate ovarian reserve and baseline estradiol levels. - Monitoring: perform regular ultrasound and hormone monitoring to detect excessive response. - Hypersensitivity: avoid in patients with known allergy to gonadotropins or excipients. - Cysts or tumors: contraindicated in the presence of ovarian cysts or estrogen‑dependent neoplasms. - Thyroid disease: use caution in uncontrolled thyroid disorders. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menotrophin may interact with other agents that influence ovarian function or coagulation.

Major Interactions (Avoid): - GnRH agonists: can cause excessive ovarian stimulation when combined. - hCG: increases risk of severe ovarian hyperstimulation syndrome. - Estrogen‑containing contraceptives: may blunt the intended gonadotropin effect.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened thrombosis risk if severe OHSS develops. - Corticosteroids: may alter follicular response and hormone levels.